Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
$4.75M
Mr. James G. Cullem J.D.
13.00
Cambridge, MA
Dec 21, 2021
-0.31
$-10.98
1.81
2.01
-11,380.36%
-4.01
0.00
2.58
43.01
2.01
-41.27%
-704.78%
Similar stocks (10)
Immix Biopharma, Inc.
IMMX
Virios Therapeutics, Inc.
VIRI
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Phio Pharmaceuticals Corp.
PHIO
Kiromic BioPharma, Inc.
KRBP
ZyVersa Therapeutics, Inc.
ZVSA
Quoin Pharmaceuticals, Ltd.
QNRX
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
Similar stocks (10)
Immix Biopharma, Inc.
IMMX
Virios Therapeutics, Inc.
VIRI
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Phio Pharmaceuticals Corp.
PHIO
Kiromic BioPharma, Inc.
KRBP
ZyVersa Therapeutics, Inc.
ZVSA
Quoin Pharmaceuticals, Ltd.
QNRX
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB